Literature DB >> 24333189

Androgen receptor identification in the diagnosis of eyelid sebaceous carcinomas.

Frederick A Jakobiec1, Xiang Werdich2.   

Abstract

PURPOSE: To assess the role of androgen receptor detection in diagnosing eyelid sebaceous carcinomas and to compare it with that of adipophilin.
DESIGN: Retrospective, clinicopathologic study.
METHODS: Ten sebaceous carcinomas (8 invasive, 2 intraepithelial only) were stained immunohistochemically for androgen receptors and were compared with adipophilin staining. Receptor staining also was performed on benign sebaceous tumors (a sebaceoma and an adenoma) and as controls on eyelid basal cell carcinomas, eyelid squamous cell carcinomas, conjunctival squamous dysplasias, and conjunctival melanomas.
RESULTS: All 8 patients with an invasive component of sebaceous carcinoma underwent a biopsy in which the tumor cells showed diffusely positive results for androgen receptors (>20% of cells and usually >40%) and positive results for adipophilin. Eight cases displaying an intraepithelial (or pagetoid) component of spread also showed diffusely positive results for androgen receptors and adipophilin in at least 1 of multiple biopsy samples from each patient. However, in 8 of 21 separate conjunctival biopsy specimens with intraepithelial cytologic atypia, adipophilin results were negative. A sebaceoma and a sebaceous adenoma also showed positive results for both of these biomarkers. Among the controls, squamous carcinomas and melanomas showed negative results for androgen receptors and adipophilin. Basal cell carcinomas displayed focal receptor positivity in fewer than 5% of cells and showed negative results for adipophilin.
CONCLUSIONS: Androgen receptors and adipophilin can separate sebaceous tumors immunohistochemically from squamous carcinomas and melanomas, which showed negative results for both, and from basal cell carcinomas, which showed positive receptor results in a distant minority of cells. Regarding intraepithelial (or pagetoid) spread, androgen receptor detection was more sensitive and reliable than adipophilin in highlighting this component of the disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24333189     DOI: 10.1016/j.ajo.2013.12.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Villous Sebaceous Adenoma Arising from the Caruncular Surface Squamous Epithelium.

Authors:  Frederick A Jakobiec; Paula Cortes Barrantes; Tatyana Milman
Journal:  Ocul Oncol Pathol       Date:  2020-03-10

2.  Sebaceous gland carcinoma of the ocular adnexa - variability in clinical and histological appearance with analysis of immunohistochemical staining patterns.

Authors:  Eva Janine Schmitz; Martina C Herwig-Carl; Frank G Holz; Karin U Loeffler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-24       Impact factor: 3.117

Review 3.  [Differential diagnostics of sebaceous tumors].

Authors:  A Böer-Auer
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

Review 4.  The association between nuclear receptors and ocular diseases.

Authors:  Ke Liu; Chang Zou; Bo Qin
Journal:  Oncotarget       Date:  2017-04-18

5.  Clear Cell Variant of Squamous Cell Carcinoma of Eyelid, Mimicking Sebaceous Carcinoma: A Rare Case Report.

Authors:  Sonali Dixit; Priyanka Gogoi; Preeti Diwaker
Journal:  J Microsc Ultrastruct       Date:  2021-01-09

6.  Morphological Spectrum of Orbitoocular Diseases in a Tertiary Health Centre in Keffi, North Central Nigeria.

Authors:  Ifeyinwa Mary Onwubuya; Tunde Mark Owoyele; Olaejirinde Olaniyi Olaofe; Kevin Nwabueze Ezike
Journal:  Adv Med       Date:  2015-10-20

Review 7.  Update on conjunctival pathology.

Authors:  Hardeep Singh Mudhar
Journal:  Indian J Ophthalmol       Date:  2017-09       Impact factor: 1.848

8.  Management of recurrent sebaceous gland carcinoma.

Authors:  Lindsay A McGrath; Zanna I Currie; Hardeep Singh Mudhar; Jennifer H Y Tan; Sachin M Salvi
Journal:  Eye (Lond)       Date:  2020-01-02       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.